Meridian Bioscience, Inc. company was founded in 1976 and is based in Cincinnati, Ohio. Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

NeoPharm, Inc. was founded in 1990 and is headquartered in Lake Bluff, Illinois. NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases primarily in the United States. Its products include LEP-ETU, which is in Phase II trial for the treatment of breast and ovarian cancer; LE-DT that is in Phase I trial for the treatment of various forms of cancer; and LE-rafAON, which completed preclinical studies to treat pancreatic cancer. The company has a co-operative research and development agreement with the National Institute of Neurological Diseases and Stroke for research on a therapeutic agent for untreatable brain diseases in humans. NeoPharm would provide its proprietary drug, Cintredekin Besudotox (IL13-PE38QQR), and technical resources to study its effects in various brain cancers in humans. Its IL13-PE38QQR also completed preclinical studies for the treatment of idiopathic pulmonary fibrosis and asthma. The company was formerly known as OncoMed, Inc. and changed its name to NeoPharm, Inc. in March 1995.

CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

Actavis is Icelandic for generic. Iceland-based Actavis Group is one of the world's largest generic pharmaceuticals producers. Actavis company has about 350 drugs in its development pipeline, and nearly 1,000 products on the market across a variety of therapeutic classes (among them cardiovascular, gastrointestinal, and oncology). It also manufactures generic hospital products, including antibiotics, anesthetics, and painkillers. Actavis makes drugs in pill, injectable, suppository, and other forms. Subsidiary Medis distributes its drugs worldwide. Actavis, which was founded in 1956, is controlled by chairman Thor Bjorgolfsson through his investment vehicle Novator. At the company's helm is CEO Sigurdur Oli Olafsson.

GTx, Inc. company was founded in 1997 and is headquartered Memphis, Tennessee. GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial.GTx it also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx's preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN.

Dainippon Sumitomo Pharma (DSP) is Osaka's answer to disease. The Japanese drugmaker produces drugs in a wide range of therapeutic categories including cardiovascular disease, gastrointestinal disorders, and infections. Its products include blood pressure medication Amlodin, digestive tract treatment Gasmotin, and antibiotic Meropen. Subsidiary Sepracordevelops and markets central nervous system and respiratory drugs in North America; its top selling product is insomnia therapy Lunesta. In addition to pharmaceuticals, DSP makes food and feed additives, veterinary drugs, fine chemicals, and diagnostic reagents used in research and clinical laboratories. Sumitomo Chemical owns just over half of DSP.

EquiTech Corporation company focuses on improving the effectiveness of commonly used drugs primarily by enhancing the absorbtion of the drugs. Its ZAG-1701 is a fast-acting ibuprofen pill designed to treat pain, including dental, fractural, and post-operative incision pain as well as migraines and other headaches. EquiTech has a strategic partnership with fellow Canadian company Ethypharm Inc., developer and manufacturer of drug delivery systems. EquiTech company was founded by chief scientific officer Fakhreddin Jamali after he discovered that absorption of pain medication is slowed when a patient is in pain.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.